Seastar Investor
reacted to
$SeaStar Medical (ICU.US)$ John Neuman is on the board of directors and the recent filing shows that he has spent over $150k of his own money buying shares.
3
Seastar Investor
reacted to
$SeaStar Medical (ICU.US)$
The NEuTRALIZE-AKI trial, with a planned enrollment of 200 subjects, will be the largest pivotal trial to date assessing the safety and efficacy of the SCD, with the aim of reducing mortality and dialysis dependence in adult patients with AKI and multiorgan dysfunction requiring CRRT. It was designed in part based on key lessons learned from past studies. First, the protocol mandates strict adherence by clinical sites tomaintaining circuit iCa levels below 0.4mmol/L, as it is within this range that highly activated white blood cells, specifically neutrophils and monocytes, are immunomodulated by the SCD to less inflammatory states [29]. Second, sites are required to commit non-bindingly to using the SCD for at least 96h to ensure that the patient receives the maximum clinical benefit from the continuous leukocyte immunomod- ulation provided by the SCD [29]. Third, dialysis dependence is included as a component of the primary study endpoint, which is a composite of mortality and dialysis dependence assessed 90 days post-randomization. There is compelling evi- dence from previous studies that the SCD promotes organ recovery, and this effect may persist well beyond the ICu stay [19–24]. Fourth, C-reactive protein (CRP) is used as a marker to screen out potentially ‘hypoinflammatory’ subtypes of patients who may have lower chances of responding to therapy with the SCD. Eligible subjects must have CRP levels of at least 3.5mg/dL.
...
The NEuTRALIZE-AKI trial, with a planned enrollment of 200 subjects, will be the largest pivotal trial to date assessing the safety and efficacy of the SCD, with the aim of reducing mortality and dialysis dependence in adult patients with AKI and multiorgan dysfunction requiring CRRT. It was designed in part based on key lessons learned from past studies. First, the protocol mandates strict adherence by clinical sites tomaintaining circuit iCa levels below 0.4mmol/L, as it is within this range that highly activated white blood cells, specifically neutrophils and monocytes, are immunomodulated by the SCD to less inflammatory states [29]. Second, sites are required to commit non-bindingly to using the SCD for at least 96h to ensure that the patient receives the maximum clinical benefit from the continuous leukocyte immunomod- ulation provided by the SCD [29]. Third, dialysis dependence is included as a component of the primary study endpoint, which is a composite of mortality and dialysis dependence assessed 90 days post-randomization. There is compelling evi- dence from previous studies that the SCD promotes organ recovery, and this effect may persist well beyond the ICu stay [19–24]. Fourth, C-reactive protein (CRP) is used as a marker to screen out potentially ‘hypoinflammatory’ subtypes of patients who may have lower chances of responding to therapy with the SCD. Eligible subjects must have CRP levels of at least 3.5mg/dL.
...
2
Seastar Investor
reacted to and commented on
$SeaStar Medical (ICU.US)$ now thats some nice price movement, i'm buying every dip from now on
1
2
Seastar Investor
commented on
$SeaStar Medical (ICU.US)$ dilution
3
Seastar Investor
reacted to and commented on
$SeaStar Medical (ICU.US)$ vacuum back up to vwap after lunch
2
1
Seastar Investor
commented on
$SeaStar Medical (ICU.US)$ Just selled 3000 shares 1week ago sad
9
Seastar Investor
reacted to
$SeaStar Medical (ICU.US)$ we problably looking at another R/S soon
3
![[empty]](https://static.moomoo.com/node_futunn_nnq/assets/images/folder.5c37692712.png)
![[error]](https://static.moomoo.com/node_futunn_nnq/assets/images/no-network.991ae8055c.png)
![[loading]](data:image/svg+xml;base64,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)